Peptides DB
Research-centric peptide and protocol reference hub

Cartalax (AED peptide) record · updated 6h ago

Healing & recoveryInflammation & immuneGrade C · preclinicalResearch use only
All 4 studiesJump to the evidenceCompare
What is Cartalax (AED peptide) used for?

Cartalax (AED) is a synthetic Khavinson tripeptide researched as a cartilage and connective tissue bioregulator, with most evidence drawn from Russian preclinical and gerontology work.

Primarily researched for · Healing & recovery

Development stage

where Cartalax (AED peptide) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 1 registered trial. It describes the research record, not a recommendation.

Identity
NameCartalax (AED peptide)
Chain length
Molecular weight333.3 Da
FormulaC12H19N3O8
Structure typeSmall molecule
ClassHealing
Research levelEmerging
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 87815447. No verified residue count for this compound.

Pharmacology
Mechanism
Route
Half-life
Time to peak
Duration
Extraction confidence
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 13, 2026. How this works →
Research stats
Total studies4
Human / animal / cellular0 / 1 / 1
Highest trial phasePreclinical
Years covered2020–2025
Latest study2mo ago
Publication history
20202025
Research funding
no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work
Community reports
Positive Neutral Negative
Records

Study register

4 rowsOpen in the library →
StudyTypeYearSummary depth
Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies.
TakeawayThe review highlights the role of fibroblast senescence in skin aging and explores emerging therapeutic strategies, though empirical validation is needed.
review2025Full text read0.80
Seizure-related death exhibits a circadian rhythm independent of seizure timing or sleep in a mouse model of Dravet syndrome.
FindingNot reported in abstract.
Animal2025Full text read0.80
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.
TakeawayThis review highlights the importance of POT and LAT transporters in the cellular transport of ultrashort peptides, but lacks specific data to support clinical applications.
review2022Full text read0.70
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
FindingTERT gene expression increased eightfold in 'stationary' aging cultures.
In vitro2020Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cartalax (AED peptide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Cartalax (AED peptide) is discussed should be drawn from it.